Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Merck
McKinsey
Express Scripts
Moodys
Harvard Business School
AstraZeneca

Last Updated: December 14, 2019

DrugPatentWatch Database Preview

Indium in-111 pentetreotide kit - Generic Drug Details

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What are the generic sources for indium in-111 pentetreotide kit and what is the scope of patent protection?

Indium in-111 pentetreotide kit is the generic ingredient in one branded drug marketed by Curium and is included in one NDA. Additional information is available in the individual branded drug profile pages.

There are twenty-four drug master file entries for indium in-111 pentetreotide kit. One supplier is listed for this compound.

Summary for indium in-111 pentetreotide kit
Recent Clinical Trials for indium in-111 pentetreotide kit

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University Hospital, Basel, SwitzerlandPhase 1/Phase 2
University Hospital Inselspital, BernePhase 1/Phase 2
University of BernPhase 1/Phase 2

See all indium in-111 pentetreotide kit clinical trials

Synonyms for indium in-111 pentetreotide kit
111In-Pentetreotide
159201-00-0
AC1MIXSA
D02108
Indium In 111 pentetreotide (USP)
Indium in 111 pentetreotide [USAN]
LS-186657
OctreoScan (TN)

US Patents and Regulatory Information for indium in-111 pentetreotide kit

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Curium OCTREOSCAN indium in-111 pentetreotide kit INJECTABLE;INJECTION 020314-001 Jun 2, 1994 RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for indium in-111 pentetreotide kit

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Curium OCTREOSCAN indium in-111 pentetreotide kit INJECTABLE;INJECTION 020314-001 Jun 2, 1994   Start Trial   Start Trial
Curium OCTREOSCAN indium in-111 pentetreotide kit INJECTABLE;INJECTION 020314-001 Jun 2, 1994   Start Trial   Start Trial
Curium OCTREOSCAN indium in-111 pentetreotide kit INJECTABLE;INJECTION 020314-001 Jun 2, 1994   Start Trial   Start Trial
Curium OCTREOSCAN indium in-111 pentetreotide kit INJECTABLE;INJECTION 020314-001 Jun 2, 1994   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Harvard Business School
Baxter
Moodys
Boehringer Ingelheim
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.